^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    STA551

    i
    Other names: STA551, Switch antibody molecule, STA 551, STA-551
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    16d
    STA101JG: A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours (2023-508764-30-00)
    P1, N=30, Active, not recruiting, Chugai Pharmaceutical Co. Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P1
    Enrollment closed • Phase classification
    |
    Tecentriq (atezolizumab) • STA551
    almost4years
    Single cell RNA sequencing revealed that the mechanism of the synergistic efficacy of STA551 and immune checkpoint inhibitor results from the induction of highly activated T cells in tumor (AACR 2022)
    The combination of STA551 and PD-L1 showed synergistic anti-tumor efficacy in a colon38-bearing human CD137 knock-in mouse model. Detailed mechanistic analysis showed that the combination of STA551 and PD-L1 induced highly activated CD8+T cells expressing chemokines and cytokines compared to monotherapy. This cluster also express chemokines, suggesting that other immune cells have been recruited.
    Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    STA551